AI Terminal
HealthBeacon SHA
Declaration of Voting Results & Voting Rights Announcements • Aug 31, 2023
1975_rns_2023-08-31_a72512c9-b65c-467c-8df2-92570007e38e.html
Declaration of Voting Results & Voting Rights Announcements
Open in ViewerOpens in native device viewer
National Storage Mechanism | Additional information 
RNS Number : 9921K
HealthBeacon PLC
31 August 2023
31 August 2023
HealthBeacon plc
Results of Annual General Meeting
Each of the resolutions proposed at the Company's Annual General Meeting, held on 31 August 2023, was passed by way of poll. The table below sets out the results of the poll on each resolution as set out in the 2023 Notice of Annual General Meeting, which is available on the Company's website www.healthbeacon.com
| Resolution | Total Votes | For | % | Against | % | Withheld | Withheld % | |
| 01 | Approval of financial statements and reports | 4,844,220 | 4,844,220 | 100.00% | - | 0.00% | - | 0.00% |
| 02 | Approval of remuneration report | 4,844,220 | 4,844,220 | 100.00% | - | 0.00% | - | 0.00% |
| 03A | Re-elect Robert Garber | 4,844,220 | 4,844,220 | 100.00% | - | 0.00% | - | 0.00% |
| 03B | Re-elect Jim Joyce | 4,836,139 | 4,836,139 | 100.00% | - | 0.00% | 8,081 | 0.17% |
| 03C | Re-elect Rebecca Shanahan | 4,844,220 | 4,844,220 | 100.00% | - | 0.00% | - | 0.00% |
| 03D | Re-elect Mary Harney | 4,844,220 | 4,844,220 | 100.00% | - | 0.00% | - | 0.00% |
| 03E | Re-elect Leo Toole | 4,844,220 | 4,844,220 | 100.00% | - | 0.00% | - | 0.00% |
| 04 | Remuneration of auditors | 4,844,220 | 4,755,793 | 98.17% | 88,427 | 1.83% | - | 0.00% |
| 05 | Authority to allot shares | 4,844,220 | 4,844,220 | 100.00% | - | 0.00% | - | 0.00% |
| 06 | Adoption of LTIP | 4,836,139 | 4,747,712 | 98.17% | 88,427 | 1.83% | 8,081 | 0.17% |
| 07 | Disapplication of pre-emption up to 10% | 4,836,139 | 4,836,139 | 100.00% | - | 0.00% | 8,081 | 0.17% |
| 08 | Disapplication of pre-emption up to an additional 10% | 4,836,139 | 4,836,139 | 100.00% | - | 0.00% | 8,081 | 0.17% |
| 09 | Authority to purchase the Company's ordinary shares | 4,844,220 | 4,844,220 | 100.00% | - | 0.00% | - | 0.00% |
| 10 | Authority to re-issue treasury shares | 4,844,220 | 4,844,220 | 100.00% | - | 0.00% | - | 0.00% |
For further information, contact:
| Enquiries: | |
| HealthBeacon: Kieran Daly Lar Malone |
[email protected] |
| Goodbody (Euronext Listing Sponsor and Broker): David Kearney |
+353 (1) 667 0420 |
| Stephen Kane | |
| Drury (Public Relations): | |
| Billy Murphy | +353 (0) 87 231 3085 |
| Paul Clifford | +353 (0) 87 327 2161 |
About HealthBeacon
Headquartered in Dublin, HealthBeacon is an Irish digital therapeutics company that
develops smart tools for managing medications for patients in the home.
The HealthBeacon Injection Care Management System tracks adherence and persistence with medication schedules through the provision of medication management reminders, safe and sustainable sharps disposal devices, educational tools, and artificial intelligence (AI) driven data analytics.
Peer reviewed evidence supports a 19% improvement in therapy persistence by patients and up to 26% improvement in adherence to therapy, which improves clinical outcomes and significantly improves efficiency in health systems.
The Company has expanded its offering to growth management with the launch of its
integrated Smart Scale and oral adherence with the launch of HB Wave which integrates
with its existing technology.
The Company operates across Europe, North America and the United Kingdom and employs more than 70 people and has obtained more than 30 design and utility patents.
The Company's mission is to become the world's leading digital therapeutics platform for patients managing medications in the home.
Ends
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
ISEBBGDILSXDGXB